Incyte Corporation (NASDAQ:INCY) has earned an average rating of “Buy” from the twenty-eight research firms that are presently covering the company, Marketbeat Ratings reports. Eight analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $143.93.

A number of equities research analysts have recently commented on the stock. TheStreet upgraded shares of Incyte Corporation from a “d+” rating to a “c” rating in a report on Wednesday, May 24th. Cowen and Company reiterated a “buy” rating on shares of Incyte Corporation in a report on Monday, June 5th. Credit Suisse Group reiterated a “buy” rating on shares of Incyte Corporation in a report on Saturday, June 10th. BMO Capital Markets reiterated an “outperform” rating and set a $166.00 price target (up previously from $155.00) on shares of Incyte Corporation in a report on Monday, June 5th. Finally, Oppenheimer Holdings, Inc. set a $135.00 price target on shares of Incyte Corporation and gave the company a “hold” rating in a report on Tuesday, June 6th.

TRADEMARK VIOLATION WARNING: “Incyte Corporation (INCY) Receives Consensus Rating of “Buy” from Analysts” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/09/16/incyte-corporation-incy-receives-consensus-rating-of-buy-from-analysts.html.

Shares of Incyte Corporation (INCY) traded down 0.51% during mid-day trading on Friday, hitting $119.15. The stock had a trading volume of 2,995,901 shares. The firm’s market capitalization is $24.51 billion. Incyte Corporation has a 1-year low of $81.49 and a 1-year high of $153.15. The stock’s 50-day moving average is $127.40 and its 200 day moving average is $130.21.

Incyte Corporation (NASDAQ:INCY) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.01). The business had revenue of $326.40 million during the quarter, compared to analysts’ expectations of $318.45 million. Incyte Corporation had a negative return on equity of 21.57% and a negative net margin of 11.77%. Incyte Corporation’s revenue for the quarter was up 32.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.18 EPS. Equities research analysts predict that Incyte Corporation will post ($0.84) EPS for the current fiscal year.

In other Incyte Corporation news, EVP Barry P. Flannelly sold 714 shares of the stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $124.25, for a total value of $88,714.50. Following the transaction, the executive vice president now directly owns 15,496 shares in the company, valued at $1,925,378. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bros. Advisors Lp Baker purchased 100,000 shares of the firm’s stock in a transaction on Friday, September 8th. The stock was acquired at an average price of $132.00 per share, for a total transaction of $13,200,000.00. The disclosure for this purchase can be found here. Insiders sold 54,252 shares of company stock worth $7,206,984 over the last quarter. Insiders own 17.70% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Incyte Corporation by 11.1% during the 2nd quarter. Vanguard Group Inc. now owns 17,125,542 shares of the biopharmaceutical company’s stock valued at $2,156,276,000 after purchasing an additional 1,709,685 shares during the period. State Street Corp raised its position in shares of Incyte Corporation by 110.7% during the 1st quarter. State Street Corp now owns 7,581,684 shares of the biopharmaceutical company’s stock valued at $1,013,437,000 after purchasing an additional 3,983,207 shares during the period. Capital International Investors raised its position in shares of Incyte Corporation by 4.0% during the 2nd quarter. Capital International Investors now owns 6,407,197 shares of the biopharmaceutical company’s stock valued at $806,730,000 after purchasing an additional 246,134 shares during the period. BB Biotech AG raised its position in shares of Incyte Corporation by 0.7% during the 2nd quarter. BB Biotech AG now owns 3,514,822 shares of the biopharmaceutical company’s stock valued at $442,551,000 after purchasing an additional 25,000 shares during the period. Finally, FMR LLC raised its position in shares of Incyte Corporation by 8.0% during the 1st quarter. FMR LLC now owns 2,980,864 shares of the biopharmaceutical company’s stock valued at $398,452,000 after purchasing an additional 219,923 shares during the period. Hedge funds and other institutional investors own 91.06% of the company’s stock.

Incyte Corporation Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Analyst Recommendations for Incyte Corporation (NASDAQ:INCY)

Receive News & Stock Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related stocks with our FREE daily email newsletter.